1789 TT

ScinoPharm Investor Conference

— 2023 12 07

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Company Overview

02 Business Update

03 Financial Performance



Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 76 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 920 active DMFs worldwide with 67 US DMFs*
- 200+ contract projects with 11 approved/launched (9 NCEs) and 6 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority
- Injectable plant certified by US FDA and TFDA

*As of 2023/10/31



Business Updates

Optimize Generic API Portfolio

Generic API Portfolio



Optimize Generic API Portfolio

2023 Generic API Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
Generic API	Bimatoprost	CN(✓)	Glaucoma	Allergan
Generic API	Cladribine	CN	Multiple sclerosis	Merck
Generic API	Galantamine HBr	CN(✓)	Alzheimer's disease	Janssen
Generic API	Azacitidine	EU	Myelodysplastic syndromes	Celgene

✓ : Approved

As of 2023/10/31

Expand CDMO Business

CDMO Business Status



As of 2023/10/31

Expand CDMO Business

2023 CDMO Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
CDMO API	Ganaxolone	EU(✓)	Genetic epilepsy	Marinus
CDMO API	Eflornithine	US/EU	FAP	Post-marketing Disclosure
CDMO API	Eflornithine	US/EU	Pediatric neuroblastoma	Post-marketing disclosure
Intermediate for CDMO API	Sotagliflozin	US(✓)	Heart failure	Lexicon

✓ : Approved

As of 2023/10/31

Advancing to Injectables

In-House Drug Product Submission Status



* Responded to FDA CRL

Advancing to Injectables

Collaborative Projects for Drug Product

Collaboration on 505(b)(2) for non-small cell lung cancer	Launched in US by customer
Collaboration on ANDA for non-small cell lung cancer	Launched in US and EU by customer
Collaboration on ANDA for multiple myeloma	Launched in the US and EU and submitted to other regions by customer
In-house Prefilled-syringe Product	Recognized by marketing partner and ANDA review is in the final stage
Contract Manufacturing of oncology Injectable	Ongoing shipment of CMO products
In-house Cartridge Product	ANDA submitted to FDA and marketing partner to be confirmed

China Market

- 4 CFDI on-site inspections completed in Changshu site to facilitate China market growth

	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate*	2021.05	Urea cycle disorders	Orphan disease medicine
2021.02	Donafenib	2021.06	Advanced liver cancer Thyroid cancer	2023 sales projected by research report : c. RMB 680 million
2021.06	Bimatoprost	2023.02	Glaucoma	Prostaglandin drug products c. RMB 1 billion
2022.11	Azilsartan	2022.09	Hypertension	c. RMB 100 million

* Customer's clinical trial for new indication in progress

- Changshu site expects to conduct more inspections



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	3Q 2023		YoY	3Q 2022	
Revenue	2,063	100%	-8%	2,248	100%
Gross Profit	758	37%	-14%	884	39%
Operating Expenses	(635)	-31%	5%	(604)	-27%
Operating Profit	123	6%	-56%	280	12%
Net Profit before Tax	158	8%	-50%	314	14%
Net Profit after Tax	130	6%	-48%	252	11%
EPS (NTD)	0.16	-	-	0.32	-

Sales Distribution – By Business





Unit: USD/M

	Generic API	CDMO	Drug Product
3Q 2023 Sales	46.4	13.4	6.8
YoY	-8.4%	2.8%	-47.9%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
3Q 2023 Sales	44.3	13.1	9.2
YoY	-16.0%	-20.3%	21.7%

Sales Distribution – By Region





Unit: USD/M

	US & Canada	EU	Japan	India	China	Others
3Q 2023 Sales	10.6	13.8	11.5	11.9	8.8	10.0
YoY	-42.4%	-11.2%	-18.0%	3.7%	20.6%	-0.1%

Consolidated Balance Sheet

NTD Million	2023/09/30		2022/09/30	
Cash and Cash Equivalents	3,995	35%	4,246	36%
Accounts Receivable	364	3%	339	3%
Inventories	1,642	14%	1,304	11%
Property, Plant & Equipment	3,653	32%	3,913	33%
Other Current/Non-Current Assets	1,913	16%	1,937	17%
Total Assets	**11,567**	**100%**	**11,739**	**100%**
Financial Debt	58	1%	49	0%
Other Current Liabilities	638	5%	629	5%
Other Non-Current Liabilities	629	5%	665	6%
Total Liabilities	**1,325**	**11%**	**1,343**	**11%**
Total Shareholders' Equities	**10,242**	**89%**	**10,396**	**89%**

Consolidated Cash Flow Statement

NTD million	3Q 2023	3Q 2022	Dif.
From Operating Activities	**173**	**669**	**-496**
Depreciation & Amortization	344	323	21
From Investing Activities	**(157)**	**(172)**	**15**
Capital Expenditure	(209)	(168)	-41
From Financing Activities	**(313)**	**(341)**	**28**
Effect of foreign exchange rate changes	**(2)**	**9**	**-11**
Net Change in Cash	**(300)**	**165**	**-465**
Beginning Balance	**4,295**	**4,081**	**214**
Ending Balance	**3,995**	**4,246**	**-251**



Q & A

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT